Article Text

Download PDFPDF

79 Activity of chemotherapy in recurrent uterine serous carcinoma
  1. R Beavers,
  2. B Fellman,
  3. M Eyada,
  4. A Klopp,
  5. N Fleming,
  6. K Lu,
  7. P Soliman and
  8. S Westin
  1. University of Texas MD Anderson Cancer Center, USA


Background Uterine serous carcinoma (USC) carries a poor prognosis and the majority of patients develop recurrence. The study objective was to compare efficacy of chemotherapy regimens in recurrent USC.

Methods A retrospective review of patients with USC treated at our institution from 1993 to 2012 was performed. Recurrence-free survival (RFS) was estimated using methods of Kaplan and Meier and modeled via Cox proportional hazards regression. RFS1 was calculated from date of first recurrence to second recurrence. Platinum-sensitivity was defined as recurrence >6 months after platinum-based therapy. Those never exposed to chemotherapy during adjuvant therapy were included in the platinum-sensitive cohort.

Results Of 313 patients, 147 (47%) had recurrence. Median age was 64 years; 65% were stage III/IV. Median follow up was 39.3 months. Median RFS1 was 5.5 months (95% CI 0.7 – 31.4). 115 patients (78%) received chemotherapy alone. Objective response was highest in the platinum-sensitive compared with the platinum-resistant cohort ((21/84; 25%) vs. (4/35; 11%)). In platinum-sensitive disease treated with chemotherapy, platinum-based had higher response compared to non-platinum-based regimens (18/44(41%) vs 3/41(7%) p=0.029). Response in platinum-resistant tumors to platinum-based regimens was 37%(3/8). 86% of patients with platinum-resistance had progressive disease regardless of chemotherapy. 86 patients (27%) had a second recurrence, 47(55%) were platinum-sensitive and 36(77%) were treated with chemotherapy. Response to chemotherapy was 5% in those with a second recurrence.

Conclusion In patients with recurrent USC deemed platinum-sensitive at first recurrence, platinum-based regimens may be associated with improved response. Platinum-resistant tumors do not appear to have an optimal second-line chemotherapy regimen.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.